Beating the Odds: Next-Gen Therapies in Heart Disease
Biotech Primer
Expert-Led Life Sciences Training and Certifications for Non-Scientists to Advance Your Career
by Emma Bardsley PhD
The cardiovascular disease (CVD) pharmaceutical landscape is as diverse as the conditions it aims to treat. Amidst the challenges posed by generic competition, efficacy, and adherence, the field is witnessing a surge in innovative treatments aimed at addressing the different facets of heart disease.
Why Heart Disease Matters
Heart disease is the leading cause of death in the US and claims the lives of nearly 1 million Americans each year. Beyond the human toll, its economic impact is staggering, with CVD incurring $407.3 billion in direct and indirect costs and projected to increase, highlighting the need for more effective treatments.
Biotech Primer Inc. provides engaging, interactive training courses tailored for non-scientists in the Biotechnology, Pharmaceutical, Molecular Diagnostics and Medical Device sectors. These courses, developed by industry experts, simplify complex scientific and regulatory concepts for professionals seeking to navigate and contribute effectively to the healthcare sector. With flexible learning options like on-demand online classes and live sessions, Biotech Primer has educated over 150,000 professionals since 2001, making it a go-to resource for understanding the science behind healthcare innovation.